Information Details

Tips for verifying the founder's resume

2023/08/24

As a VC who looks at the direction of biomedicine, when we get BP, we pay attention to nothing more than the founding team, the company's development history, industry overview, product technology, business model, competitors and other aspects. According to the resume of the founding team, we can analyze the founder's resource endowment, strategic market, execution, management and marketing capabilities. The company's development history, industry overview, product technology, and business model are often easier to verify, and the relatively large part is in the founding team's resume (is it exaggerated?). ) and competitors (is the analysis comprehensive, are the advantages and disadvantages of each company hidden?) ）。

We often say that practice makes true knowledge, we look at what the founder can do in the past, to speculate what he can do now and in the future, especially in the field of new drug research and development, if the founder has had successful drug research and development experience in the field of new drug research and development, it is often a big plus for the project, when BP describes that a founder has hosted or led a drug listing in a company, how do we verify the authenticity of this resume? The following Xiaobian will use a few cases to share some tips for resume verification.

Entry-level: Verified by articles published by founders

In the new Henglida continuous follow-up project Sunris, BP described that the founder Dr. Luo is a postdoctoral fellow at the University of California, Berlick, under the tutelage of Academician Jay D. Keasling (the initiator of Amyris, a leading synthetic biology company in the United States), and his postdoctoral work was mainly in the synthesis of cannabinoids in yeast, and the article was published in Nature. Then the verification is very simple, open PubMed, enter the keywords, as follows:

After PubMed searched, found the article, Dr. Luo Xiaozhou is the joint first author, the corresponding author is Jay D. Keasling, click on Affiliations can also see the author's unit, it is indeed the University of California, Berkeley, you can also download the literature directly, as shown below:

Through the article, we found that the resume is real and the project can continue to follow.

Advanced class: through domestic public channels (such as prospectuses of listed companies, patents, etc.) for verification

Taking Lingda Biologics recently obtained by Xiaobian as an example, BP described the founder Dr. Shen Jingkang as a successful practitioner of new drug innovation, and reached hundreds of millions of yuan in contract transactions with Mabwell, Meiyak, Luoxin, Haihe and other companies, the project is in clinical phase 1-2 (SCC244 and SCC31) in China and the United States, SCC244 has been recognized as a breakthrough therapy, and the marketing application has been accepted.

Then we can search for SCC244 in the search engine and find that it is a product of Haihe Company, knowing that Haihe Pharmaceutical has been reported for IPO, and there is a public prospectus, which can be found from the prospectus. First searched for Shen Jingkang's name in the prospectus, but to no avail. A search for SCC244 then found that BP described SCC244 as in the marketing application stage (update: SCC244 has been conditionally approved for marketing as of now) and the contract amount is correct.

The above information can only show that SCC244 is indeed transferred from drugs at the NDA application stage, with an amount of more than 244 million yuan, but it does not prove that SCC244 was invented by Dr. Shen Jingkang. So what do we do? Check the patent for SCC<>!

We then searched for SCC244 in the prospectus and found that the patent did not specify who the inventor was, but knew that the patent name was a class of five-membered heterocyclic pyridine compounds and their preparation methods and uses, and the application number was 2013102453548, then we can download the patent on the Chinese patent download website. Open the Chinese patent download website, enter the application number, and you can download the patent, as shown below:

从这份专利中，可以看到专利权人和发明人，发现沈竞康博士确实SCC244药物的第一发明人，创始人履历求证无误。

当然，也有其他渠道查找沈竞康博士是否是该专利的发明人，不一定要通过下载专利，比如，在百度学术或百度文库中，输入专利名称，即可看到专利的发明人和摘要，或者在企查查中，输入公司名字，在知识产权的专利部分可以直接看到专利发明人名字。

Another drug is SCC31, we searched in the search engine and found that SCC31 was transferred to Luoxin Pharmaceutical, but the public information only mentioned Professor Yu Ke, not Dr. Shen Jingkang, and found that SCC31 is a dual inhibitor of mTORC1 and mTORC2 targets.

Next, Qi Cha searched for Luoxin Pharmaceutical Company, and found the patent containing both Shen Jingkang and Yu Ke, as shown in the figure below, click on the details to see, it is indeed an mTOR inhibitor, knowing the application number and public announcement number, you can also download and confirm on the Chinese patent download website, the method is the same as above.

Then check the clinical stage of SCC31, you can search directly on the ClinicalTrials.gov website, if you can't search, it may be a different name code. Taking SCC31 as an example, if the search on the ClinicalTrials.gov website is fruitless, go to adisinsight to search, and find that SCC31 is in clinical phase 1, and Luoxin Pharmaceutical has changed to its own company's code, as shown below:

可以接着在ClinicalTrials.gov网站搜索LXI15029，了解该药物的更多临床信息。

通过以上专利求证，已确认创始人履历的真实性。

Challenge level: Verification through foreign public channels (such as LinkedIn, patents, etc.).

The above case is that the drug invented by the founder's unit in China is transferred to a domestic company, which is relatively easy to check, if a project BP describes that the founder has led a drug to be successfully marketed in a foreign company, or entered clinical phase I-II-III, how can we verify it?

Taking the Keba Biotech project that Xiaobian came into contact with as an example, BP described that the founder Dr. Zhu Guidong has nearly 30 years of experience in innovative drug research and development, is one of the most successful Chinese scientists in Abbott/AbbVie, and is the inventor of Veliparib and 5 other clinical new drugs, Veliparib is being filed for marketing (NDA) in the US FDA. We know that the drug research and development cycle is long, the cost is high and the risk is high, and the drug is easy to be imitated, so the dependence of the biopharmaceutical industry on intellectual property rights is very high, and the protection of pharmaceutical intellectual property rights by pharmaceutical companies also runs through the entire life cycle of drugs.

First of all, through the search engine (personally like to use Bing, foreign information use Bing international version) to understand the basic information of Veliparib, found that Veliparib is an inhibitor of PARP1 and PARP2, the pipeline code is ABT-888.

THEN WE CAN SEARCH THROUGH THE LENS ORG'S FREE PATENT WEBSITE.

Start by entering the name of the founder, as shown above, there are 396 patents. There are too many patents, you can then filter and filter at Inventors and/or Owners on the right, BP describes working for Abbott/AbbVie, just select Abbott/AbbVie.

过滤后有27项专利（往往一个专利在多个国家申请的），点击专利名称进去，可以下载或查看专利pdf，发现以上两个专利均与PARP抑制剂相关，一个是化合物结构，一个是晶型制备相关，基本可以确认朱博士是药物Veliparib的发明人，另外发现朱博士在艾伯维还有CDK9抑制剂、MCL-1抑制剂相关发明。

以上是通过专利查找一个创始人是否曾在某公司任职，是否具体领导或参与了某药物的开发的简单方法。

In addition, you can also try to find someone's work resume directly in the search engine, such as Xiaobian in the leading investment seed round Biaojing project, in Bing International version of the input "Jinling li + keywords", you can search for relevant information on the relevant workplace social pages, Xiaobian has seen its resume in the LinkedIn and Apollo website, and there are also related magazine reports, as follows:

The resumes of the founders of the above cases are real, of course, the editor has also contacted some case project founders' resumes that are exaggerated, so I will not expand the specific introduction here.

In general, the founder's resume is only part of the project, but also combined with the industry track, product technology and other aspects to comprehensively consider a project, and finally wish everyone a good project.

Practice of Reviewing Venture Capital - Realizing Chapter

An article on OCT